News stories about Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) have been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Verona Pharma plc – American Depositary Share earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9566711321935 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Verona Pharma plc – American Depositary Share (NASDAQ VRNA) traded up $0.20 during trading on Monday, reaching $12.52. The company had a trading volume of 100 shares, compared to its average volume of 8,675. Verona Pharma plc – American Depositary Share has a 1-year low of $10.44 and a 1-year high of $17.50.
Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) last announced its earnings results on Tuesday, November 7th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.40). equities analysts expect that Verona Pharma plc – American Depositary Share will post -2.8 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Verona Pharma plc – American Depositary Share (VRNA) Receiving Somewhat Favorable News Coverage, Analysis Shows” was first reported by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/verona-pharma-plc-american-depositary-share-vrna-given-coverage-optimism-score-of-0-21/1819100.html.
About Verona Pharma plc – American Depositary Share
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.